Comparing two dinoprostone agents for preinduction cervical ripening at term. A randomized trial.
OBJECTIVE
To compare the safety, efficacy and cost of two methods of administering commercially available dinoprostone for preinduction cervical ripening at term.


METHODS
Sixty-nine women admitted for labor induction were randomized to receive one of two commercially available agents for cervical ripening. Half the patients received a gel containing 0.5 mg of dinoprostone placed intracervically every four hours. The other half received a polymer insert containing 10 mg of dinoprostone intravaginally. After 12 hours of cervical ripening, oxytocin was given and amniotomy performed to induce labor.


RESULTS
Among 69 women randomized, 35 received the gel and 34 the polymer. No significant differences were noted between the two groups in starting characteristics or indication for induction. Both groups were similar with respect to change in Bishop score, start-to-delivery interval, amount of oxytocin required, mode of delivery and success of induction. A slightly higher rate of hyperstimulation was noted in the polymer group, although this did not lead to fetal or maternal morbidity. The average costs per patient for the two agents were similar.


CONCLUSIONS
The two dinoprostone agents are similar with respect to efficacy. The polymer group had slightly more complications but without adverse fetal or maternal outcomes. A larger, multicenter trial would be required to determine actual differences in the efficacy, safety and cost of these two agents.
Wieland
D
D
Department of Obstetrics and Gynecology, Jacobi Medical Center, Bronx, NY 10461, USA.
Friedman
F
F
D000293:Adolescent; D000328:Adult; D020070:Cervical Ripening; D002626:Chemistry, Pharmaceutical; D015232:Dinoprostone / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs; D005260:Female; D005782:Gels; D017048:Health Care Costs; D006801:Humans; D007751:Labor, Induced; D010120:Oxytocics / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D011108:Polymers; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies
D005782:Gels; D010120:Oxytocics; D011108:Polymers; D015232:Dinoprostone